QSC PHARMA GRADE
🇮🇳 India Warehouse105-Count Pack
What is Piclib 125mg (1X21) (PALBOCICLIB)?
CDK4/6 inhibitor for hormone receptor-positive, HER2-negative advanced/metastatic breast cancer — combined with letrozole or fulvestrant as standard first and second-line treatment.
How it Works
Inhibits cyclin-dependent kinases 4 and 6 (CDK4/6) — prevents Rb phosphorylation and cell cycle progression from G1 to S phase, halting tumor proliferation.
Quick Specs
| Form | Oral tablets — pre-dosed |
| Active Ingredient | PALBOCICLIB |
| Dose per Tablet | 125MG |
| Pack Size | 105 tablets |
| Storage | Room temperature (15–25°C), cool dry place |
| Shelf Life | 2–3 years (properly stored) |
Common Side Effects
Neutropenia (very common and dose-limiting), fatigue, nausea, infections, mouth sores, diarrhea, alopecia, anemia, thrombocytopenia.
Safety Warnings
⚠️ CBC monitoring mandatory (weekly for first 2 cycles, monthly thereafter). Dose reductions for grade 3/4 neutropenia. QT prolongation risk. CYP3A4 substrate — multiple interactions. Embryofetal toxicity.
Shipping: 🇮🇳 India Warehouse — international delivery
